Pay in 4 interest-free payments of $5.23 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Mosharov et al
It is primarily indicated for those experiencing significant gastrointestinal losses (vomiting or diarrhoea) or inadequate food and fluid intake, rather than routine use for all GLP-1 users
She is Chair of the National Eating Disorders Collaboration Steering Committee in Australia and was a member of the ICD-11 Working Group for Eating Disorders and was Chair of the Clinical Practice Guidelines Project Working Group (Eating Disorders) of RANZCP
doi: 10.7759/cureus.52709 18
US$ 27.85
US$ 21.28
US$ 27.96
